ClinicalTrials.gg
TerminatedNCT00620074Updated Feb 15, 2010Results posted

Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

A Phase 4 interventional study of voriconazole and anidulafungin in Aspergillosis, sponsored by Pfizer. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-15.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Why this study was terminated
See Detailed Description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.

Enrollment
15th of 17
6 · median 24
Started
2008
with 2 others
Phase 4
4 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
6 of 17
Pfizer

Among the 17 studies testing voriconazole in Aspergillosis, this one is the 15th largest by enrollment, is one of 3 that started in 2008, is one of 4 in phase 4, and was the 7th registered.

Aspergillosis

134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.

Browse Aspergillosis studies →

Open to participants now

None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →

About voriconazole

Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing voriconazole in Aspergillosis as a file.
02

Study summary

This study will test the effectiveness and the safety of giving two antifungal agents (voriconazole and anidulafungin) together to treat invasive aspergillosis in patients who are unable to tolerate polyene therapy.

Read the detailed description

The study was terminated on January 12, 2009 due to the overall low rate of enrollment. The decision to terminate the trial was not based on any safety concerns. Patients who were enrolled in the study prior to January 12, 2009 were allowed to remain in the study until completing their participation as specified in the protocol.

03

Conditions studied

  • Aspergillosis

Browse trials for

Keywords

  • invasive aspergillosis, opportunistic mold infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Proven or probable invasive aspergillosis. Patient is intolerant to polyene therapy.

Exclusion criteria

Exclusion Criteria:

Patients with invasive aspergillosis for more than 30 days at the time of study entry. Patients with uncontrolled bacterial or viral infection at the time of study entry. Patients with significant liver dysfunction or who are taking certain medications which interact with voriconazole.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    combination 2

    anidulafungin plus voriconazole

    Drug: voriconazole

  • Experimental
    combination 1

    anidulafungin plus voriconazole

    Drug: anidulafungin

Interventions

  • Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance \<50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).

    Also known as: Vfend

  • Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy

    Also known as: Eraxis

06

What researchers measure

Primary outcomes

  1. Summary of Global Response at End of Treatment (EOT)

    Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.

    Time frame: End of Treatment (Day 42)

Secondary outcomes

  1. Summary of Global Response at Week 2, Week 4, and Week 6

    Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.

    Time frame: Week 2, Week 4, Week 6

  2. Summary of Mortality

    Number of subects with documented mortality (death).

    Time frame: Up to Week 6

  3. Galactomannan Titer Assay Levels and Global Response

    Number of subjects per Galactomannan titer level with global response for all subjects (with or without renal impairment). The galactomann assay is an immunological blood serum test used to diagnose invasive aspergillosis and to monitor disease progression. Global response is a composite of clinical and radiological findings summarized as Complete Response: resolution of all clinical signs and symptoms; Partial Response: clinical improvement; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.

    Time frame: Up to Week 6

  4. Voriconazole Trough Levels With Intravenous and Oral Dosing

    Voriconazole trough plasma concentrations measured as nanograms per milliliter (ng/mL).

    Time frame: Week 1 through Week 6

07

Results

Posted Feb 15, 2010
Limitations and caveats
Due to low enrollment and early termination of the study, data was insufficient for descriptive or inferential analysis as planned; no significant treatment-related safety results were identified in the subjects treated with combination therapy.

Participant flow

Participant flow — Overall Study
MilestoneAnidulalfungin and Voriconazole
Started6
Completed5
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimarySummary of Global Response at End of Treatment (EOT)

Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.

Time frame:
End of Treatment (Day 42)
Reported as:
Number · participants
Summary of Global Response at End of Treatment (EOT)
participantsAnidulalfungin and Voriconazole
Failure (No response)1
Partial response3
Stable response0
Complete response2
SecondarySummary of Global Response at Week 2, Week 4, and Week 6

Number of subjects with global response consisting of a combination of clinical and radiological findings at the end of therapy. Possible outcome categories: Complete Response: resolution of all clinical signs and symptoms and more than 90% of lesions due to invasive aspergillosis that were visible on radiological studies; Partial Response: clinical improvement and greater than 50% improvement in radiological findings; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.

Time frame:
Week 2, Week 4, Week 6
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondarySummary of Mortality

Number of subects with documented mortality (death).

Time frame:
Up to Week 6
Reported as:
Number · participants
Summary of Mortality
participantsAnidulalfungin and Voriconazole
Summary of Mortality1
SecondaryGalactomannan Titer Assay Levels and Global Response

Number of subjects per Galactomannan titer level with global response for all subjects (with or without renal impairment). The galactomann assay is an immunological blood serum test used to diagnose invasive aspergillosis and to monitor disease progression. Global response is a composite of clinical and radiological findings summarized as Complete Response: resolution of all clinical signs and symptoms; Partial Response: clinical improvement; Stable Response: no change from baseline or an improvement of less than 50% in radiological findings; Failure (no response): worsening disease.

Time frame:
Up to Week 6
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryVoriconazole Trough Levels With Intravenous and Oral Dosing

Voriconazole trough plasma concentrations measured as nanograms per milliliter (ng/mL).

Time frame:
Week 1 through Week 6
Reported as:
Mean · ng/mL

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anidulalfungin and Voriconazole—4/6 (66.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventAnidulalfungin and Voriconazole
Disease progressionGeneral disorders1/6
Renal failure acuteRenal and urinary disorders1/6
HydropneumothoraxRespiratory, thoracic and mediastinal disorders1/6
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/6
Respiratory failureRespiratory, thoracic and mediastinal disorders1/6
Most frequent other events
Showing 10 of 25
Most frequent other events
EventAnidulalfungin and Voriconazole
Cardiac failure congestiveCardiac disorders2/6
VomitingGastrointestinal disorders2/6
AnaemiaBlood and lymphatic system disorders1/6
LeukocytosisBlood and lymphatic system disorders1/6
DiarrhoeaGastrointestinal disorders1/6
HaematemesisGastrointestinal disorders1/6
NauseaGastrointestinal disorders1/6
PyrexiaGeneral disorders1/6
Oropharyngeal candidiasisInfections and infestations1/6
Blood glucose increasedInvestigations1/6

Baseline characteristics

Age, Customized
Age, Customized(participants)Anidulalfungin and Voriconazole
Between 57 and 83 years6
Sex: Female, Male
Sex: Female, Male(Participants)Anidulalfungin and Voriconazole
Female1
Male5
08

Study locations

4 sites
  • Pfizer Investigational Site
    Atlanta, Georgia 30322, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76104, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76107, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2008
First posted
Feb 21, 2008
Start
Aug 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Feb 15, 2010
Last update
Feb 15, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00620074
Lead sponsor
Pfizer
First posted
Feb 21, 2008
Start date
Aug 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Feb 15, 2010
Last update
Feb 15, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Voriconazole · Anidulafungin

Start the discussion